https://www.businesswire.com/news/home/20260328320362/en/AAD-2026-Late-Breaking-Nemolizumab-Data-Demonstrate-Clinically-Meaningful-Benefits-for-Children-Aged-2-to-11-With-Moderate-to-Severe-Atopic-Dermatitis
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children...
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with modera...
aad 2026